Asker Healthcare Group (ASKER) Q1 2025 earnings summary

Executive summary

• Q1 2025 marked the first quarterly report post-IPO, with strong business momentum, steady profitable growth, and successful execution of strategic initiatives.

• Net sales rose 16% year-over-year to SEK 3,995m, with 6% organic growth and 10% from acquisitions.

• Adjusted EBITDA/EBITA grew 17% to SEK 364m, with margin improvement to 9.1%, progressing toward the 10% target.

• Twelve acquisitions completed in the last 12 months, including HSL in Northern Ireland and Mayumana Healthcare in the Netherlands, supporting international expansion.

• IPO in March 2025 raised SEK 1.5bn, with SEK 1.2bn used to repay debt, reducing net debt/EBITDA from 2.2x to 1.7x and broadening the shareholder base.

Financial highlights

• Net sales up 16% year-over-year to SEK 3,995m; adjusted EBITDA/EBITA up 17% to SEK 364m; margin at 9.1%.

• Organic EBITDA/EBITA growth was 6%, with acquired growth at 10-12%; minor negative FX impact.

• Return on net working capital (EBITA/NWC) reached 66.5%, exceeding the 50% internal target.

• Net debt/EBITDA improved to 1.7x, supported by IPO proceeds and EBITDA growth.

• Cash flow from operating activities was lower in Q1 due to acquisition-related working capital build-up and tax settlements.

Outlook and guidance

• Expectation to continue outpacing market growth, targeting 10-20 acquisitions per year and at least 10% acquired EBITDA growth annually.

• Margin improvement expected to continue gradually toward 10% through operational excellence and scale.

• FX translation effects expected to be more significant in Q2–Q4; minor product sourcing in USD may provide upside later in the year.

• Management sees ongoing opportunities for market consolidation and international expansion, supported by a strong acquisition pipeline and robust balance sheet.

• Stable demand expected due to demographic trends and resilient healthcare sector.